BURLINGTON, N.C., Dec. 30, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that the company will participate in a fireside chat at the 44th Annual J.P.

Shares of Labcorp Holdings Inc. (NYSE: LH - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the fifteen analysts that are covering the company, MarketBeat.com reports. Four analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The average 12 month price objective

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Labcorp's strategic partnerships, specialty test growth and more attractive valuation tilt the balance as it emerges stronger than Hologic right now.

Osaic Holdings Inc. increased its stake in shares of Labcorp Holdings Inc. (NYSE: LH) by 13.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 38,620 shares of the medical research company's stock after purchasing an additional 4,690

Assenagon Asset Management S.A. decreased its holdings in shares of Labcorp Holdings Inc. (NYSE: LH) by 69.8% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 36,212 shares of the medical research company's stock after selling 83,746 shares during the quarter. Assenagon Asset

Bartlett and CO. Wealth Management LLC cut its stake in Labcorp Holdings Inc. (NYSE: LH) by 1.2% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 208,210 shares of the medical research company's stock after selling 2,595 shares during

Investors need to pay close attention to LH stock based on the movements in the options market lately.

ST. LOUIS--(BUSINESS WIRE)--Cofactor Genomics, a commercial-stage diagnostics company transforming precision oncology through RNA-based predictive tests, today announced strategic investments from Labcorp and Ascension Ventures. The financing is intended to accelerate Cofactor's nationwide expansion and broaden patient access to its immunotherapy-response diagnostics. Ascension Ventures, the strategic investment arm of 13 leading U.S. health systems across 22 states, representing more than $100.

Cerity Partners LLC decreased its position in Labcorp Holdings Inc. (NYSE: LH) by 2.8% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 82,469 shares of the medical research company's stock after selling 2,348 shares during the period. Cerity